SAB Biotherapeutics (SABS) Current Leases (2020 - 2025)
Historic Current Leases for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $837286.0.
- SAB Biotherapeutics' Current Leases rose 11753.79% to $837286.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $837286.0, marking a year-over-year increase of 11753.79%. This contributed to the annual value of $393430.0 for FY2024, which is 4127.44% down from last year.
- As of Q3 2025, SAB Biotherapeutics' Current Leases stood at $837286.0, which was up 11753.79% from $815064.0 recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Current Leases ranged from a high of $1.2 million in Q3 2022 and a low of $384892.0 during Q3 2024
- In the last 5 years, SAB Biotherapeutics' Current Leases had a median value of $607955.0 in 2023 and averaged $728636.1.
- As far as peak fluctuations go, SAB Biotherapeutics' Current Leases crashed by 5703.88% in 2022, and later soared by 11753.79% in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Current Leases stood at $1.1 million in 2021, then plummeted by 57.04% to $490794.0 in 2022, then skyrocketed by 36.5% to $669946.0 in 2023, then plummeted by 41.27% to $393430.0 in 2024, then skyrocketed by 112.82% to $837286.0 in 2025.
- Its last three reported values are $837286.0 in Q3 2025, $815064.0 for Q2 2025, and $793360.0 during Q1 2025.